Abstract

Aim . To create a model for non-alcoholic fatty liver disease (NAFLD) development at the steatosis stage in visceral obesity in patients with coronary artery disease (CAD) and hypertension (HTN). Material and methods . The study included male patients with coronary artery disease, stable angina and hypertension: experimental group — 75 patients, control group — 38 patients. All patients underwent an anthropometric assessment, visualization and measurement of the intraabdominal fat thickness (AIFT) and epicardial fat thickness (EFT) by ultrasound, and echocardiography. The liver state was assessed using clinical and functional biochemical tests and ultrasound. Lipid and carbohydrate metabolism parameters was also evaluated. The influence of each of the studied indicators on NAFLD development was determined using the factor and correlation analysis. Results. We created a mathematical model for predicting the NAFLD at the steatosis stage. Using significant variables (body mass index (BMI), EFT, AIFT, left ventricular posterior wall thickness (LVPWT), Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) value), a regression model was created. There was following resulting regression equation: prognostic index K= -24,9+0,81 х BMI+1,06 х EFT+0,02 х AIGT+0,6 х LVPWT-1,07 х HOMA-IR. To test the developed model, a double-blind randomized study was performed. At K<9,37, the risk of NAFLD can be regarded as low, at K>15,38 — as high. Values from 9,37 to 15,38 are considered intermediate. Conclusion . During the study, an original model was developed to calculate the likelihood of NAFLD development. The resulting model with the assessment of risk factors in patients with CAN and HTN with visceral obesity can be used to plan a prevention strategy. Patented invention №2718325RU dated 01.04.2020.

Highlights

  • An original model was developed to calculate the likelihood of non-alcoholic fatty liver disease (NAFLD) development

  • Выведенная формула с проградуированной оценкой факторов риска (ФР) у больных ишемической болезнью сердца (ИБС) и артериальной гипертензией (АГ) с висцеральному ожирению (ВО) может использоваться для прогнозирования развития жировой дистрофии печени с целью планирования стратегии профилактики, направленной на замедление развития сосудистые заболевания (ССЗ) и их осложнений

Read more

Summary

Introduction

В.* — д.м.н., профессор кафедры госпитальной терапии c курсами кардиологии, функциональной диагностики ФПК и ПП, ORCID: 00000002-8544-8423, Рязанова Т. А. — ассистент кафедры госпитальной терапии с курсами кардиологии и функциональной диагностики, ORCID: 0000-00023567-3972, Пономарев С.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.